Skip to main content

Table 3 Functional information for drugs and drug targets identified by bioinformatic screening of genes that are consistently upregulated or downregulated in soft tissue sarcomas, across three species. Screening of sets of 53 genes that are upregulated in sarcoma and 38 genes that are downregulated was performed using the Enrichr web tool (see Methods and Fig. 6)

From: Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach

gene set drug or target comment reference
up in sarcoma piperlongumine-1764 natural product with anti-cancer properties [44]
up in sarcoma TGFA (transforming growth factor ɑ) targeted for immunotoxin therapy [45]
up in sarcoma FGF7 (fibroblast growth factor 7) proposed therapeutic target [46]
up in sarcoma saracatinib (AZD-0530) investigational anti-cancer drug; dual-kinase inhibitor (Src and Bcr-Abl) [47]
up in sarcoma MK-2206 investigational anti-cancer drug; selective protein kinase B (Akt) inhibitor [48]
up in sarcoma linsitinib (OSI-906) investigational anti-cancer drug; inhibitor of insulin receptor and insulin-like growth factor 1 receptor [49]
up in sarcoma GSK-1059615 phosphatidylinositol 3-kinase inhibitor and mTOR inhibitor [50]
down in sarcoma PDGFBB (platelet-derived growth factor BB monomer) frequently drives sarcoma growth via autocrine signaling [51]
down in sarcoma rosiglitazone peroxisome proliferator-activated receptor-ɣ agonist [52]
down in sarcoma HGF (hepatocyte growth factor) HGF-MET signaling axis implicated in soft tissue sarcoma proliferation [53]
down in sarcoma AS601245 c-Jun N-terminal kinase inhibitor; proposed as a co-therapeutic with rosiglitazone [54]
down in sarcoma PD0325901 mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) inhibitor [55]
down in sarcoma GSK-J4 prodrug of GSK J1, a selective inhibitor of H3K27 histone demethylases JMJD3 and UTX [56]
down in sarcoma AS605240 phosphatidylinositol 3-kinase inhibitor [57]
down in sarcoma selumetnib
(AZD-6244, ARRY-142886)
ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2; investigational cancer drug [58]